Alzheimer’s disease is the most common cause of dementia, affecting millions of people around the world.
The condition slowly damages the brain, leading to memory loss, confusion, personality changes, and difficulty carrying out everyday activities. As the disease progresses, many people eventually need full-time care and support from family members or healthcare professionals.
For decades, scientists have focused on two major features of Alzheimer’s disease: amyloid plaques and tau tangles. These abnormal protein deposits build up inside the brain and are considered key signs of the disease.
Many treatments have been designed to reduce or remove these proteins. Although some newer medicines can slow the progression of Alzheimer’s in certain patients, they cannot stop the disease completely or restore lost memories.
In recent years, researchers have begun paying closer attention to another possible driver of Alzheimer’s disease: chronic inflammation in the brain. Inflammation is normally a protective response used by the immune system to fight infections and repair damage.
Inside the brain, specialized immune cells help clear harmful substances and support healthy nerve cells. However, when this immune response remains active for too long, it can begin damaging healthy brain tissue.
Scientists now believe that this ongoing inflammation, often called neuroinflammation, may play an important role in the progression of Alzheimer’s disease. Rather than simply being a side effect, inflammation may actively contribute to the destruction of neurons and worsening symptoms.
A new study published in the journal eNeuro explored whether cannabidiol, commonly known as CBD, could help reduce this harmful inflammation. CBD is a natural compound found in cannabis plants.
Unlike THC, another well-known cannabis compound, CBD does not produce a “high.” Over the past decade, scientists have investigated CBD for a wide range of potential health benefits, including pain relief, anxiety reduction, epilepsy treatment, and brain protection.
The new research was led by Babak Baban and colleagues at Augusta University. The team used a well-established mouse model of Alzheimer’s disease to investigate how CBD affects inflammation in the central nervous system, which includes the brain and spinal cord.
The researchers delivered CBD through inhalation and then examined changes in the animals’ immune systems and brain tissues. Using advanced molecular and genetic techniques, they measured several biological markers linked to inflammation.
The results were encouraging. The scientists found that CBD reduced the activity of several key pathways involved in neuroinflammation. The treatment also lowered levels of pro-inflammatory molecules, which are substances that can worsen inflammation and contribute to brain damage.
The team discovered that CBD appeared to influence multiple immune-related pathways at the same time. This is important because Alzheimer’s disease is a highly complex condition involving many biological processes rather than a single cause. Researchers increasingly believe that successful treatments may need to target several aspects of the disease simultaneously.
According to the researchers, previous studies from their group also suggested that CBD may help reduce amyloid plaques and tau tangles through different mechanisms.
If these findings continue to hold up in future studies, CBD could potentially offer a multi-target approach by reducing inflammation while also affecting the protein abnormalities associated with Alzheimer’s disease.
However, it is important to remember that these findings are still at an early stage. The study was performed in mice, not humans. Many treatments that appear promising in animal studies ultimately fail during human clinical trials.
Researchers will need to conduct much larger studies and carefully designed clinical trials before determining whether CBD can safely and effectively help people with Alzheimer’s disease.
Despite these limitations, the study adds to growing evidence that inflammation may be a major treatment target in Alzheimer’s disease. It also highlights the potential of CBD as a compound worthy of further investigation.
Source: Augusta University.
